SCHEMBL912274

SCHEMBL912274

COCC1CCCN1C(=O)Nc1cccc(Nc2ncc(C(N)=O)c(NCc3ccccc3)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 12/20 0.55
CAMK1D Q8IU85 1/20 0.53
JAK1 P23458 3/20 0.52
JAK3 P52333 3/20 0.52
SYK P43405 2/20 0.52
JAK2 O60674 2/20 0.52
NTRK1 P04629 2/20 0.48
BMPR2 Q13873 2/20 0.48
TBK1 Q9UHD2 2/20 0.48
NUAK1 O60285 1/20 0.47
STK16 O75716 1/20 0.47
CSNK2A2 P19784 1/20 0.47
TYK2 P29597 1/20 0.47
AAK1 Q2M2I8 1/20 0.47
NUAK2 Q9H093 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
BMP2K Q9NSY1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913795 1.00 STAT6 (0.55) STAT6CAMK1DJAK1JAK3SYK
SCHEMBL912273 1.00 STAT6 (0.55) STAT6CAMK1DJAK1JAK3SYK
SCHEMBL3716242 0.93 JAK3 (0.52) STAT6CAMK1DJAK1JAK3SYK
SCHEMBL3809023 0.93 JAK3 (0.52) STAT6CAMK1DJAK1JAK3SYK
SCHEMBL913703 0.89 STAT6 (0.59) STAT6JAK1JAK3SYKJAK2
SCHEMBL914128 0.89 STAT6 (0.59) STAT6JAK1JAK3SYKJAK2
SCHEMBL913701 0.89 STAT6 (0.59) STAT6JAK1JAK3SYKJAK2
SCHEMBL913149 0.87 SYK (0.51) CAMK1DSYK
SCHEMBL914107 0.87 SYK (0.51) CAMK1DSYK
SCHEMBL913148 0.87 SYK (0.51) CAMK1DSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US claimed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US claimed
WO-2010129802-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2010-11-11 WO claimed
US-8853230-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-07 US disclosed
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US disclosed
US-8367689-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US disclosed
WO-2010129802-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137673-A1 INHIBITORS OF JAK JAK1, JAK2, JAK3 STAT6 16/4885CAMK1D 677/4885JAK1 1/4885
US-20110005947-A1 INHIBITORS OF JAK JAK1, JAK2, JAK3 STAT6 16/4885CAMK1D 677/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.